USA – Arrowhead Pharmaceuticals, a company aiming to develop drugs using RNA interference technology, has announced that it has licensed an experimental medicine for a common liver disease to GlaxoSmithKline…
Read MoreArrowhead and GSK tie up to develop RNAi drug in a deal worth over US$1 billion
